Clinical Trials Logo

Clinical Trial Summary

To study will assess safety and performance of the PerQseal Elite Closure Device when used with the 18F PerQseal Elite Introducer to percutaneously close femoral artery punctures and to induce arterial haemostasis in patients undergoing endovascular procedures requiring an arteriotomy created by 14 to 22 F sheaths. Note, for reference purposes, it is expected arteriotomies created with 14 to 22 F sheaths will create an arteriotomy in the range of 16 - 26 F (being the outer diameter of these sheaths).


Clinical Trial Description

This study will be a prospective, multi-centred, non-randomized study to investigate the safety and performance of the PerQseal Elite. The study shall not be blinded prior to, during or post the procedure. All patients undergoing an endovascular procedure requiring an arteriotomy created by 14 to 22 F sheaths, via the common femoral artery will be screened against the inclusion/exclusion criteria. All subjects shall have a pre-discharge, 30-Days ± 7-Days and 180-Days ± 30-Days follow-up assessment. All safety data from the study will be assessed by the Data Safety Monitoring Committee on a continuous basis. ;


Study Design


Related Conditions & MeSH terms

  • Large Hole Percutaneous Arterial Closure

NCT number NCT05951634
Study type Interventional
Source Vivasure Medical Limited
Contact Chris Martin
Phone +353 91 395 442
Email Chris.Martin@vsuremed.com
Status Not yet recruiting
Phase N/A
Start date August 2023
Completion date September 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05323877 - Safety and Performance Study of Large Hole Vascular Closure Device - France N/A